Medical Treatments for Male and Female Pattern Hair Loss

Rogers, Nicole E.; Avram, Marc R.

doi:10.3109/9781616310073.005

Cited by 39 publications

(64 citation statements)

References 134 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[7][8][9] Current pharmacological treatments do not achieve ideal control of hair loss even in common conditions like androgenetic alopecia or alopecia areata. 10,11 The development of novel therapies is hampered by the lack of suitable hair loss model systems in animals or humans. 12 In human studies, most work is carried out on large terminal scalp follicles producing thick, frequently pigmented hairs, obtained as by-products of surgery.…”

Section: Discussionmentioning

confidence: 99%

Intermediate hair follicles: a new more clinically relevant model for hair growth investigations

Miranda

Tobin

Sharpe

et al. 2010

British Journal of Dermatology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Intermediate hair follicles: a new more clinically relevant model for hair growth investigations

Miranda

Tobin

Sharpe

et al. 2010

British Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…Unfortunately, hair loss disorders are currently poorly controlled; available therapies either have limited effectiveness or unwanted side effects (12,13). Interestingly, the main therapies for androgenetic alopecia were developed for other conditions.…”

mentioning

confidence: 99%

The prostamide‐related glaucoma therapy, bimatoprost, offers a novel approach for treating scalp alopecias

Khidhir

Woodward

Farjo³

et al. 2012

FASEB j.

View full text Add to dashboard Cite

Balding causes widespread psychological distress but is poorly controlled. The commonest treatment, minoxidil, was originally an antihypertensive drug that promoted unwanted hair. We hypothesized that another serendipitous discovery, increased eyelash growth side-effects of prostamide F2α-related eyedrops for glaucoma, may be relevant for scalp alopecias. Eyelash hairs and follicles are highly specialized and remain unaffected by androgens that inhibit scalp follicles and stimulate many others. Therefore, we investigated whether non-eyelash follicles could respond to bimatoprost, a prostamide F2α analog recently licensed for eyelash hypotrichosis. Bimatoprost, at pharmacologically selective concentrations, increased hair synthesis in scalp follicle organ culture and advanced mouse pelage hair regrowth in vivo compared to vehicle alone. A prostamide receptor antagonist blocked isolated follicle growth, confirming a direct, receptor-mediated mechanism within follicles; RT-PCR analysis identified 3 relevant receptor genes in scalp follicles in vivo. Receptors were located in the key follicle regulator, the dermal papilla, by analyzing individual follicular structures and immunohistochemistry. Thus, bimatoprost stimulates human scalp follicles in culture and rodent pelage follicles in vivo, mirroring eyelash behavior, and scalp follicles contain bimatoprost-sensitive prostamide receptors in vivo. This highlights a new follicular signaling system and confirms that bimatoprost offers a novel, low-risk therapeutic approach for scalp alopecias.—Khidhir, K. G., Woodward, D. F., Farjo, N. P., Farjo, B. K., Tang, E. S., Wang, J. W., Picksley, S. M., and Randall, V. A. The prostamide-related glaucoma therapy, bimatoprost, offers a novel approach for treating scalp alopecias.

show abstract

“…He went even further advising dermatologists to "cease using finasteride and non-sprescription blockers of "the bad body chemical dihydrotestosterone (DHT) for alopecia." Further articles in dermatology literature followed the same course, although were less substantial with the risk of prostate cancer (3,4). The purpose of this review is to clarify the data from PCPT and asses the real risk of prostate cancer when prescribing finasteride for androgenic alopecia.…”

Section: Introductiond Th_1358 544546mentioning

confidence: 99%

“…. Deductively, male pattern baldness may be safely treated with finasteride at a dose of 1 mg per day without concern for increased risk of developing high grade prostatic cancer 4…”

mentioning

confidence: 99%

THERAPEUTIC HOTLINE: Treatment of androgenic alopecia with finasteride may result in a high grade prostate cancer in patients: fact or fiction?

Lynn

Krunic

2010

Dermatologic Therapy

View full text Add to dashboard Cite

Finasteride at a dose of 1 mg (Propecia®) has been used for the treatment of androgenic alopecia in men. Though finasteride has been successfully used, there is ongoing controversy surrounding its use since the publication of the Prostate Cancer Prevention Trial (PCPT) which includes claims of increased risk for higher grade prostate cancers. This has produced confusion on consulting and treatment of patients interested in starting finasteride for androgenic alopecia. We felt there was a need to clarify further the results of PCPT for our readers and help understanding the real risk of prostate cancer development of patients on finasteride. In conclusion, we suggest the guidelines for treatment monitoring for patients on finasteride which based on comprehensive review of the trial presents safe treatment for androgenetic alopecia without the concern for the induction of high-grade prostate cancer.

show abstract

Medical Treatments for Male and Female Pattern Hair Loss

Cited by 39 publications

References 134 publications

Intermediate hair follicles: a new more clinically relevant model for hair growth investigations

Intermediate hair follicles: a new more clinically relevant model for hair growth investigations

The prostamide‐related glaucoma therapy, bimatoprost, offers a novel approach for treating scalp alopecias

THERAPEUTIC HOTLINE: Treatment of androgenic alopecia with finasteride may result in a high grade prostate cancer in patients: fact or fiction?

Contact Info

Product

Resources

About